Selected Scientific Publications

William (Bill) Cavanagh

The publications below reflect Bill Cavanagh's earlier scientific work in prostate cancer, radiation oncology, brachytherapy, cancer immunotherapy, and related areas.

Cavanagh W, Tjoa BA, Ragde H. Chemotherapy followed by syngeneic dendritic cell injection in the mouse: findings and implications for human treatment. Urology. 2007;70(6):36-41.

Ragde H, Cavanagh WA, Tjoa BA. Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. Journal of Urology. 2004;172:2532-2538.

Cavanagh W, Blasko JC, Grimm PD, Sylvester JE. Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer. Seminars in Urologic Oncology. 2000;18:160-165.

Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. International Journal of Radiation Oncology, Biology, Physics. 2001;51:31-40.

Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak D, Cavanagh W. Palladium-103 brachytherapy for prostate carcinoma. International Journal of Radiation Oncology, Biology, Physics. 2000;46:839-850.

Blasko JC, Grimm PD, Sylvester JE, Cavanagh W. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiotherapy & Oncology. 2000;57:273-278.

Wallner K, Merrick G, True L, Sherertz T, Sutlief S, Cavanagh W, Butler W. 20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial. Radiotherapy & Oncology. 2005;75:307-310.

Tran A, Wallner K, Merrick G, Seeberger J, Armstrong J, Mueller A, Cavanagh W, Lin D, Butler W. Rectal fistulas after prostate brachytherapy. International Journal of Radiation Oncology, Biology, Physics. 2005;63:150-154.

Herstein A, Wallner K, Merrick G, Mitsuyama H, Armstrong J, True L, Cavanagh W, Butler W. I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial. Cancer Journal. 2005;11:385-389.

Sherertz T, Wallner K, Merrick G, Cavanagh W, Butler W, Reed D, True L. The prognostic significance of Gleason pattern 5 in prostate cancer patients treated with Pd-103 plus beam radiation therapy. Cancer Journal. 2004;10:301-306.

Sherertz T, Wallner K, Merrick G, Ford E, Sutlief S, Cavanagh W, Butler W, True L. Factors predictive of rectal bleeding after 103Pd and supplemental beam radiation for prostate cancer. Brachytherapy. 2004;3:130-135.

Mueller A, Wallner K, Merrick G, Ford E, Sutlief S, Cavanagh W, Butler W. Perirectal seeds as a risk factor for prostate brachytherapy-related rectal bleeding. International Journal of Radiation Oncology, Biology, Physics. 2004;59:1047-1052.

Fagundes HM, Keys RJ, Wojcik MF, Radden MA, Bertelsman CG, Cavanagh WA. Transperineal TRUS-guided prostate brachytherapy using loose seeds versus RAPIDStrand: a dosimetric analysis. Brachytherapy. 2004;3:136-140.

Choi S, Wallner KE, Merrick GS, Cavanagh W, Butler WM. Treatment margins predict biochemical outcomes after prostate brachytherapy. Cancer Journal. 2004;10:175-180.

Wallner K, Merrick G, True L, Sutlief S, Cavanagh W, Butler W. 125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial. International Journal of Radiation Oncology, Biology, Physics. 2003;57:1297-1303.

Ghaly M, Wallner K, Merrick G, True L, Sutlief S, Cavanagh W, Butler W. The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: morbidity outcomes from two prospective randomized multicenter trials. International Journal of Radiation Oncology, Biology, Physics. 2003;55:1288-1293.

Corriveau J, Wallner K, Merrick G, True L, Cavanagh W, Sutlief S, Butler W. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy. Brachytherapy. 2003;2:108-113.

Wallner K, Merrick G, True L, Cavanagh W, Simpson C, Butler W. I-125 versus Pd-103 for low-risk prostate cancer: morbidity outcomes from a prospective randomized multicenter trial. Cancer Journal. 2002;8:67-73.

Locke J, Ellis W, Wallner K, Cavanagh W, Blasko J. Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: a prospective study. International Journal of Radiation Oncology, Biology, Physics. 2002;52:712-719.

Landis D, Wallner K, Locke J, Ellis W, Russell K, Cavanagh W, Blasko J. Late urinary function after prostate brachytherapy. Brachytherapy. 2002;1:21-26.

Blasko JC, Mate T, Sylvester JE, Grimm PD, Cavanagh W. Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes. Seminars in Radiation Oncology. 2002;12:81-94.

Sylvester J, Grimm P, Blasko J, Meier R, Spiegel J, Heaney C, Cavanagh W. The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy: a survey of practice patterns of urologists and radiation oncologists in the United States. Urology. 2001;58:65-70.

Lederman GS, Cavanagh W, Albert PS, Israeli R, Lessing J, Savino M, Volpicella F. Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external-beam radiotherapy and brachytherapy. International Journal of Radiation Oncology, Biology, Physics. 2001;49:1297-1303.

Kattan MW, Potters L, Blasko JC, Beyer DC, Fearn P, Cavanagh W, Leibel S, Scardino PT. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology. 2001;58:393-399.

Sylvester J, Blasko JC, Grimm PD, Meier R, Cavanagh W. Short-course androgen ablation combined with external-beam radiation therapy and low-dose-rate permanent brachytherapy in early-stage prostate cancer: a matched subset analysis. Molecular Urology. 2000;4:155-159; discussion 161.

Wallner K, Ellis W, Russell K, Cavanagh W, Blasko J. Use of TRUS to predict pubic arch interference of prostate brachytherapy. International Journal of Radiation Oncology, Biology, Physics. 1999;43:583-585.

Bellon J, Wallner K, Ellis W, Russell K, Cavanagh W, Blasko J. Use of pelvic CT scanning to evaluate pubic arch interference of transperineal prostate brachytherapy. International Journal of Radiation Oncology, Biology, Physics. 1999;43:579-581.

Badiozamani KR, Wallner K, Cavanagh W, Blasko J. Comparability of CT-based and TRUS-based prostate volumes. International Journal of Radiation Oncology, Biology, Physics. 1999;43:375-378.

Blasko JC, Wallner KE, Cavanagh W. Radiotherapeutic strategies in the management of clinically localized, "low-risk" prostate cancer: selection, results, and the search for answers. Cancer Journal From Scientific American. 1998;4:157-158.

Ragde H, Blasko JC, Grimm PD, Kenny GM, Sylvester JE, Hoak DC, Landin K, Cavanagh W. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer. 1997;80:442-453.

Ragde H, Blasko JC, Grimm PD, Kenny GM, Sylvester J, Hoak DC, Cavanagh W, Landin K. Brachytherapy for clinically localized prostate cancer: results at 7- and 8-year follow-up. Seminars in Surgical Oncology. 1997;13:438-443.

Prestidge BR, Hoak DC, Grimm PD, Ragde H, Cavanagh W, Blasko JC. Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer. International Journal of Radiation Oncology, Biology, Physics. 1997;37:31-39.

Blasko JC, Ragde H, Grimm PD, Cavanagh W. Prostate brachytherapy: importance of technique. Journal of Clinical Oncology. 1996;14:1965-1967.

Blasko JC, Ragde H, Luse RW, Sylvester JE, Cavanagh W, Grimm PD. Should brachytherapy be considered a therapeutic option in localized prostate cancer? Urologic Clinics of North America. 1996;23:633-650.